It was shown that urinary TMAO, but not its precursors, was correlated with the risk of CHD (n = 275) and may accelerate the development of CHD (Yu et al., 2019)
Jumping to a high dose without the adaptation period dramatically increases the risk of severe nausea, vomiting, and diarrhea
A recent systematic review of GLP-1 agonist exposure found that animal studies showed risks such as fetal growth restriction and skeletal abnormalities, and due to limited human data, experts recommend stopping these medications in both pregnancy and during breastfeeding
10.1038/s41598-017-15809-4 13
However, high TMAO was associated with chronic inflammation and high IL-6 and CRP levels in 179 patients with kidney disease [21]
TR, thyroid hormone receptor